Syngene International Ltd

Syngene International Ltd (SYNGENE) has witnessed a notable 14.2% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s ongoing bearish momentum. This surge in open interest, coupled with rising volumes and persistent price weakness, suggests evolving market positioning and potential directional bets among traders.

Syngene International Ltd, a key player in the healthcare services sector, has witnessed a notable 13.07% surge in open interest in its derivatives segment, signalling heightened market activity despite the stock’s ongoing bearish momentum. This development comes as the stock hits a fresh 52-week low, reflecting sustained selling pressure and shifting investor positioning.

Syngene International Ltd has witnessed a notable 11.4% surge in open interest in its derivatives segment, signalling heightened market activity despite the stock’s ongoing bearish momentum. The healthcare services company’s shares have been under pressure, hitting a fresh 52-week low of ₹476.15 on 28 Jan 2026, as investors grapple with sustained selling and shifting market positioning.

Syngene International Ltd has witnessed a notable 10.46% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s ongoing bearish momentum. This surge in open interest, coupled with rising volumes and deteriorating price trends, suggests a complex interplay of investor positioning and directional bets in the healthcare services small-cap.

Syngene International Ltd’s stock declined to a fresh 52-week low of Rs.476.8 today, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a combination of subdued financial results and valuation concerns.

Syngene International Ltd (SYNGENE) has witnessed a significant surge in open interest in its derivatives segment, coinciding with a sustained decline in its share price. The healthcare services company’s open interest jumped by 42.95% to 25,916 contracts, signalling heightened market activity and shifting investor positioning amid a volatile trading environment.

Syngene International Ltd, a key player in the healthcare services sector, has witnessed a significant surge in open interest in its derivatives segment, coinciding with a sustained decline in its share price. The stock’s recent performance, combined with heightened market activity, signals a complex interplay of investor positioning and potential directional bets amid volatile trading conditions.

Syngene International Ltd, a key player in the healthcare services sector, has witnessed a significant surge in open interest in its derivatives segment, coinciding with a sustained decline in its share price. The stock’s open interest jumped by 36.75% to 24,793 contracts, reflecting heightened market activity and shifting positioning among traders amid a challenging price environment.

Syngene International Ltd has witnessed a significant surge in open interest in its derivatives segment, coinciding with a sustained decline in its share price. The healthcare services company’s stock has been under pressure for nine consecutive sessions, falling over 20% during this period, while open interest in futures and options contracts jumped by 26.65%, signalling heightened market activity and shifting investor positioning.

Syngene International Ltd experienced a significant intraday decline on 27 Jan 2026, touching a new 52-week low of Rs 499.6 as the stock faced intense selling pressure. The healthcare services company underperformed its sector and broader market indices, continuing a prolonged downtrend amid a cautious market environment.

Syngene International Ltd (SYNGENE) has witnessed a significant 25.6% surge in open interest in its derivatives segment, coinciding with a sustained nine-day losing streak that has dragged the stock down by over 20%. This spike in open interest, coupled with elevated volumes and heightened volatility, signals a complex market positioning scenario as investors reassess directional bets amid weakening price momentum.

Syngene International Ltd, a key player in the healthcare services sector, has witnessed a notable 12.7% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s ongoing bearish momentum. This surge in open interest, coupled with elevated volumes and persistent price weakness, suggests a complex interplay of market positioning and directional bets among investors.

Syngene International Ltd’s stock declined sharply to a new 52-week low of Rs.502.8 today, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a combination of subdued financial results and valuation concerns.

Syngene International Ltd experienced significant intraday weakness on 23 Jan 2026, hitting a fresh 52-week low of Rs 546.8 as the stock declined by 7.77% amid broad market pressures and sector underperformance.

Syngene International Ltd’s stock price declined to a fresh 52-week low of Rs.560.9 today, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a combination of subdued financial results and valuation concerns.

Syngene International Ltd., India's leading contract research and manufacturing services organisation, reported deeply disappointing results for Q3 FY26, with consolidated net profit plunging 88.56% year-on-year to just ₹15.00 crores from ₹131.10 crores in Q3 FY25. The sharp sequential decline of 77.65% from Q2 FY26's ₹67.10 crores has sent shockwaves through the investment community, with the stock trading at ₹588.10 as of January 22, 2026, down 2.12% on the day and nursing a brutal 28.91% decline over the past year.